IP Library › Granted Patent US 9,636,410
Granted Patent B2
US 9,636,410 · App. 14/130,886 · Granted May 2, 2017

Cationic oil-in-water emulsions

Inventors: Luis Brito (Concord, MA); Michelle Chan (Florence, MA); Andrew Geall (Littleton, MA); Derek O'Hagan (Winchester, MA); Manmohan Singh (Cary, NC)
Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
A61K47/48046A61K9/1075A61K39/12A61K39/39A61K47/06A61K47/24A61K2039/5256A61K2039/53A61K2039/55555A61K2039/55566C12N2710/16134C12N2710/16734C12N2760/18534C12N2770/36134C12N2770/36143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,636,410
App. No.
14/130,886
Granted
May 2, 2017
Kind
B2
Abstract

This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid-based vaccines.

Claims (17)

1. A stable oil-in-water emulsion comprising particles that are dispersed in an aqueous continuous phase, wherein the average diameter of said particles is from about 80 nm to 150 nm, wherein the average diameter does not change by more than 10% when the emulsion is stored at 4° C. for one month; and wherein the emulsion comprises an oil and a cationic lipid, wherein the head group of the cationic lipid comprises a quaternary amine, and

wherein:

(i) the ratio of oil:lipid (mole:mole) is at least about 8:1 (mole:mole);

(ii) the concentration of cationic lipid in said emulsion is at least about 2.5 mM; and

(iii) the cationic lipid is not DC-Cholesterol.

2. The oil-in-water emulsion of claim 1 , wherein the average diameter of said particles is from about 80 nm to about 130 nm.

3. The oil-in-water emulsion of claim 1 , wherein the ratio of oil:lipid (mole:mole) is from about 10:1 (mole:mole) to about 43:1 (mole:mole).

4. The oil-in-water emulsion of claim 1 , wherein said oil-in-water emulsion comprises from about 0.2% to about 8% (w/v) oil.

5. The oil-in-water emulsion of claim 4 , wherein said oil is squalene or squalane.

6. The oil-in-water emulsion of claim 1 , wherein the oil-in-water emulsion further comprises from about 0.01% to about 2.5% (v/v) surfactant.

7. The oil-in-water emulsion of claim 6 , wherein said surfactant is SPAN85 (SorbitanTrioleate), Tween 80 (polysorbate 80), or a combination thereof.

8. The oil-in-water emulsion of claim 7 , wherein the oil-in-water emulsion comprises about 0.5% (v/v) Tween 80 and about 0.5% (v/v) SPAN85.

9. The oil-in-water emulsion of claim 1 , wherein the cationic lipid is selected from the group consisting of: 1,2-dioleoyloxy-3-(trimethylammonio)propane (DOTAP), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), and N-[1-(2, 3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA).

10. The oil-in-water emulsion of claim 9 , wherein the cationic lipid is DOTAP and the concentration of DOTAP in said emulsion is from about 2.58 mM (1.8 mg/mL) to about 7.16 mM (5 mg/mL).

11. A method for preparing the oil-in-water emulsion of claim 1 , comprising: (a) directly dissolving the cationic lipid in the oil to form an oil phase; (b) providing an aqueous phase of the emulsion; and (c) dispersing the oil phase in the aqueous phase by homogenization.

12. The method of claim 11 , wherein step (a) further comprises heating the oil to a temperature between about 30° C. to about 65° C.

13. The oil-in-water emulsion of claim 1 further comprising an antioxidant.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2016
From: BRITO, LUIS; CHAN, MICHELLE; GEALL, ANDREW; O'HAGAN, DEREK; SINGH, MANMOHAN
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 039080/0371 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2016
From: NOVARTIS VACCINES AND DIAGNOSTICS INC
To: NOVARTIS AG
Reel/Frame 039080/0384 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2016
From: NOVARTIS AG
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 039080/0409 →
Continuity (4)
Provisional Application 61505109 · Jul 6, 2011
Provisional Application 61545936 · Oct 11, 2011
Provisional Application 61585641 · Jan 11, 2012
Related Publication 20140220083A1 · Aug 7, 2014